I'm no wizard when it comes to analyzing sec filin

I'm no wizard when it comes to analyzing sec filings, but I did spot something I hadn't seen before. Doesn't mean it hasn't been mentioned and I just missed it. But with all the hope many of us have had in Cytodyn partnering up in some way, licensing LL for an indication or something else to bring in some substantial monies (and a pharma partner with more clout and resources) I thought this was notable in regards to Tyler Blok's compensation:

"The Compensation Committee determined that a fourth performance goal, relating to obtaining a material strategic partnership or licensing transaction, was not met. All performance goals were among the Company’s objectives established by the Board for fiscal year 2024."

I had been wondering what the fourth goal was that he missed.

Now it isn't a surprise that they'd be looking to do this. The idea of licensing or partnerships has been tossed about quite a bit, and I think everyone is in agreement that it's important to get one or both done to keep advancing LL.

But if you think about this for a moment, it should tell you that they believed a licensing transaction (This would be huge for all of us) or a strategic partnership (Also huge, and something that's bigger than these glio or alzheimer's initiatives, otherwise he'd be getting that last 25% of his incentive comp) is something they were fully preparing for executing in fiscal 2024.

It wasn't a part of his incentive comp for no reason. They know they need it, they anticipated there being a chance it could happen, and they were prepared to compensate him for it.

Obviously neither opportunity has occurred.

Yet.

After all, it's Cytodyn, baby. Add 25-2000% on the timeline.

But all joking aside, as we move forward it could happen at any minute? Why? Because it's laid out in the compensation plan that just expired. It's now officially overdue.

I think the hiring of Max is part of the process in getting GSK involved, and it wouldn't surprise me at all if we finally see movement on the licensing and partnership front soon. They have a lot of stuff they'll need to pay for moving forward into and through 2025. It's time to get some help in the way of money and bigger pharma resources.